FIGURE 2.
Levels of mediation by (A, B) glycated haemoglobin (HbA1c), (C, D) systolic blood pressure (SBP) and (E, F) body weight (BW) on the effect of liraglutide on time to first kidney outcome in two patient subgroups by estimated glomerular filtration rate (eGFR) from the LEADER trial. Levels of mediation are demonstrated by examining the difference between the light and dark blue lines. †Adjusted to the counterfactual probability of an event at a given time if patients in the liraglutide arm changed to mediator levels they would have experienced in the placebo arm. Kidney event was defined as a composite of (i) new‐onset persistent macroalbuminuria, (ii) persistent doubling of serum creatinine and reaching eGFR of ≤45 mL/min/1.73 m2, (iii) need for continuous renal replacement therapy, or (iv) death from kidney disease